Nyheter m m

Cision

Nuevolution AB15 min. fördröjning

Förändring0% Senast32,50 SEK
Köp Sälj Läs mer
		

Nuevolution: Nuevolutions application for delisting from Nasdaq Stockholm approved

15:00 As previously communicated by Nuevolution AB (publ) (Nuevolution) by a press release published on 11 July 2019, the board of directors of Nuevolution has resolved to apply for delisting of Nuevolutions shares from Nasdaq Stockholm. Today, Nasdaq Stockholm approved the application and resolved that the last day of trading in Nuevolutions shares will be 26 July 2019. For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 7020 0987 Email: ahg@nuevolution.com Johnny Stilou, CFO Phone: +45 8877 5973 Email: jost@nuevolution.com Information about Nuevolution AB (publ) Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolutions internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer. This information was released for publication at 15.00 CEST on 12 July 2019. Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com. ----------------------------------------------------------- https://news.cision.com/nuevolution/r/nuevolution-s-application-for-delisting-from-nasdaq-stockholm-approved,c2862545 https://mb.cision.com/Main/13526/2862545/1076916.pdf © Cision

Finansiella instrument kan både öka och minska i värde. Det finns en risk att du inte får tillbaka de pengar du investerar. Innan du investerar i en fond bör du läsa informationsbroschyren som finns hos fondbolaget och faktabladet som du hittar i orderläggningsfönstret samt på fondens produktsida på nordnet.se.